<- Go Home
Bionano Genomics, Inc.
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. The company offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. It also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic data from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, the company offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Market Cap
$11.2M
Volume
80.2K
Cash and Equivalents
$3.6M
EBITDA
-$45.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$494.0K
Profit Margin
1.74%
52 Week High
$72.60
52 Week Low
$2.68
Dividend
N/A
Price / Book Value
0.24
Price / Earnings
-0.08
Price / Tangible Book Value
0.29
Enterprise Value
$11.4M
Enterprise Value / EBITDA
-0.27
Operating Income
-$58.7M
Return on Equity
127.82%
Return on Assets
-31.04
Cash and Short Term Investments
$18.2M
Debt
$18.4M
Equity
$48.2M
Revenue
$28.5M
Unlevered FCF
$1.8M
Sector
Life Sciences Tools and Services
Category
N/A